Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase III	Treatment	Closed	16 and over	NCI, Other	CAN-NCIC-MA20 NSABP-CAN-NCIC-MA20, NCCTG-CAN-NCIC-MA20, RTOG-CAN-NCIC-MA20, SWOG-CAN-NCIC-MA20, TROG-CAN-NCIC-MA20, NCIC-MA20, NCT00005957, MA20

Special Category: CTSU trial

Objectives

1. Compare the overall survival, disease-free survival, isolated local regional disease-free survival, and distant disease-free survival in women with previously resected, early stage, invasive breast cancer treated with breast radiotherapy with or without regional radiotherapy.
2. Compare the toxic effects of these regimens in these patients.
3. Compare the quality of life of patients (in certain participating centers) treated with these regimens.
4. Compare the cosmetic outcomes in patients (in certain participating centers) treated with these regimens.

Entry Criteria

Disease Characteristics:

• Histologically proven invasive carcinoma of the breast
  • No evidence of T4, N2-3, or M1 disease prior to surgery
  • Node positive or high-risk node negative



• Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT
  • Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision
  • Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site
  • Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria
    • If node positive, then a level I and II axillary dissection must be performed
  • No evidence of residual disease in axilla after dissection



• Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy



• High risk of regional and systemic recurrence due to one of the following:
  • Pathologically positive axillary lymph nodes
  • Pathologically negative axillary lymph nodes with one of the following:
    • Primary tumor greater than 5 cm
    • Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:
      • Estrogen receptor negative
      • Skarf-Bloom-Richardson grade 3
      • Lymphovascular invasion



• Hormone receptor status:
  • Estrogen and progesterone receptor status known

Prior/Concurrent Therapy:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics
• Concurrent standard adjuvant chemotherapy allowed

Endocrine therapy:

• See Disease Characteristics
• Concurrent standard adjuvant hormonal therapy allowed

Radiotherapy:

• See Disease Characteristics

Surgery:

• See Disease Characteristics

Patient Characteristics:

Age:

• 16 and over

Sex:

• Female

Menopausal status:

• Premenopausal or postmenopausal

Performance status:

• ECOG 0-2

Life expectancy:

• At least 5 years

Hematopoietic:

• Not specified

Hepatic:

• SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*
• Alkaline phosphatase no greater than 3 times ULN*

 [Note: * Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations]

Renal:

• No serious nonmalignant renal disease

Cardiovascular:

• No serious nonmalignant cardiovascular disease

Pulmonary:

• No serious nonmalignant pulmonary disease

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception
• No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy
• No other malignancy except:
  • Nonmelanomatous skin cancer
  • Carcinoma in situ of the cervix or endometrium
  • Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)
  • Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation
• No psychiatric or addictive disorder that would preclude informed consent or study compliance

Expected Enrollment

Approximately 1,822 patients will be accrued for this study within approximately 4 years.

Outcomes

Overall survival

Disease-free survival (including locoregional and distant disease)
Toxicity assessed by NCI CTC v2.0
Quality of life assessed by the EORTC QLQ-C30, OCOG Breast Cancer Questionnaire
Cosmetic outcome according to the EORTC Breast Cancer Rating System for Cosmetic Results of Breast Conserving Treatment

Outline

This is a randomized, multicenter study. Patients are stratified according to number of positive nodes (0 vs 1-3 vs more than 3), type of chemotherapy (anthracycline containing vs other vs none), hormonal therapy (yes vs no), number of axillary lymph nodes excised*, and participating center. Patients are randomized to one of two treatment arms.

 [Note: * Patients with a negative sentinel node dissection with or without an axillary dissection will be stratified according to the total number of nodes removed]

• Arm I: Patients undergo standard breast radiotherapy alone 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.



• Arm II: Patients undergo breast and regional radiotherapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.

Radiotherapy in both arms begins as soon as possible after randomization. Radiotherapy must begin within 8 weeks after completion of adjuvant IV chemotherapy, unless radiotherapy is administered concurrently with chemotherapy (i.e., cyclophosphamide, methotrexate, and fluorouracil [CMF]), or within 16 weeks after the last breast surgery for patients treated with hormonal therapy alone.

Quality of life is assessed (in patients in certain participating centers) within 2 weeks prior to randomization, during the last week of radiotherapy, at 3 and 9 months after completion of radiotherapy, and then annually until first distant disease recurrence.

Cosmetic outcome is assessed (in patients in certain participating centers) within 2 weeks prior to randomization, and then at 3 and 5 years after completion of radiotherapy or until first distant disease recurrence.

Patients are followed at 3, 6, and 9 months, every 6 months for 2 years, and then annually thereafter.

Trial Contact Information

Trial Lead Organizations

NCIC-Clinical Trials Group

Timothy Whelan, MD, Protocol chair		Ph: 905-387-9711 ext. 64509

National Surgical Adjuvant Breast and Bowel Project

David Parda, Protocol chair		Ph: 412-359-8084; 866-680-0004 Email: dparda@wpahs.org

Radiation Therapy Oncology Group

Julia White, MD, Protocol chair		Ph: 414-805-4462 Email: jwhite@radonc.mcw.edu

Southwest Oncology Group

Lori Pierce, MD, Protocol chair		Ph: 734-764-9922; 800-865-1125

Trans-Tasman Radiation Oncological Group Incorporated

Boon Chua, MD, Protocol chair		Ph: 61-3-9656-1111 Email: Boon.Chua@petermac.org

North Central Cancer Treatment Group

Laura Vallow, MD, Protocol chair		Ph: 904-953-1040 Email: vallow.laura@mayo.edu

Registry Information
Official Title		A Phase III Study of Regional Radiation Therapy in Early Breast Cancer
Trial Start Date		2000-04-27
Registered in ClinicalTrials.gov		NCT00005957
Date Submitted to PDQ		2002-08-02
Information Last Verified		2007-02-01